Usa hospital covid-19 patient Health Usa

COVID-19 remdesivir study finds long hospital stay, but context matters

Reading now: 942

Remdesivir, the only antiviral fully approved for COVID-19 treatment by the US Food and Drug Administration (FDA), was associated with a longer hospital stay yet no improvement in survival rates, according to a real-world observational study of military veterans today in JAMA Network Open.The researchers suggest that the prescribed regimen (5 or 10 days) may have led to longer hospitalizations as patients finished the treatment course, and a related commentary agrees.Increased hospitalization timeThe study included 5,898 US patients admitted to 123 Veterans Health Administration hospitals from May 1 to Oct 8, 2020, during the drug's emergency use authorization (EUA) period, before it was formally approved by the FDA.Four in 10 patients

The website is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News